Randomized Phase III Trial on Gemcitabine Versus Mytomicin in Recurrent Superficial Bladder Cancer: Evaluation of Efficacy and Tolerance - Concepedia

Concepedia

Publication | Closed Access

Randomized Phase III Trial on Gemcitabine Versus Mytomicin in Recurrent Superficial Bladder Cancer: Evaluation of Efficacy and Tolerance

188

Citations

21

References

2009

Year

Raffaele Addeo, Michele Caraglia, Sergio Bellini, Alberto Abbruzzese, Bruno Vincenzi, Liliana Montella, Antonio Miragliuolo, Rosario Guarrasi, Michele Lanna, Gregorio Cennamo,

Journal of Clinical Oncology

Abstract

This study demonstrates that GEM has better efficacy and lower toxicity than MMC; therefore, GEM appears as a logical candidate for intrabladder therapy in patients with refractory transitional cancer.

References

	Year	Citations

Page 1